Marengo Reports Early Phase 2 Activity for Invikafusp Alfa Combination; Advances STAR Program at AACR 2026
Marengo Therapeutics announced early Phase 2 activity for its invikafusp alfa plus sacituzumab govitecan (Trodelvy) combo in metastatic breast cancer, reporting confirmed complete responses in heavily pretreated patients across both triple‑negative and hormone‑receptor‑positive/HER2‑negative cohorts. The interim safety data matched the known profiles of each agent, with no new signals. At AACR 2026 the company also highlighted its second STAR platform candidate, IPN01203/STAR0501, which entered a Phase I/II study with partner Ipsen. These milestones underscore progress of Marengo’s T‑cell‑targeted immunotherapy platform.
Kailera IPO Interview: CEO Renaud Talks Biotech Market, China and Obesity Pipeline
Kailera Therapeutics closed a record‑setting $625 million Nasdaq IPO, the largest biotech debut of the year. The company, launched with Bain Capital Life Sciences backing, leverages a portfolio of obesity drug candidates originally sourced from China’s Hengrui Medicine. CEO Renaud highlighted...
Study Finds HPV Vaccine Cuts Male Cancer Risk by Half
Researchers analyzing data from about 1 million U.S. males found that a single dose of the nine‑valent HPV vaccine slashes the risk of HPV‑related head and neck cancers by roughly 50%. The findings bolster arguments for expanding routine HPV vaccination to...
Why Do Weight Loss Drugs Work For Some And Not Others? It’s In The Genes
New research links genetic variants in the GLP‑1 and GIP receptors to the wide range of responses seen with obesity drugs. A common GLP‑1 receptor allele adds about 1.7 lb of weight loss per copy, while a GIP‑receptor variant eliminates the...
#AACR26 Preview: Revolution Medicines, the RAS Bonanza and China ADC Standouts
Revolution Medicines unveiled a pan‑RAS inhibitor that doubled overall survival for patients with recurrent or treatment‑resistant pancreatic cancer. The Phase 2 trial reported a median overall survival of roughly 12 months versus six months with standard chemotherapy. Data were presented at...
New Treatment Lets 3 Transplant Patients Halt Anti-Rejection Drugs
Researchers at the University of Pittsburgh infused donor‑derived immune cells into liver‑transplant recipients, aiming to induce immune tolerance. In an early‑stage trial of eight patients, three have remained off immunosuppressive drugs for over three years with stable graft function. The...
AI‑Driven Trials Could Propel India’s Pharma Leaders
One of the most amazing encounters at Semafor World Economy was with Satish Reddy of Dr. @bindureddy's Laboratories , the largest or second largest pharma company in India, depending on how you look at it. Now, they are also looking...
Age Shapes Melanoma Progression and Immune Response
Researchers at Fox Chase Cancer Center presented evidence that melanoma metastasis follows a non‑linear age curve in mice: low in young animals, peaking in middle‑aged subjects, and declining in very old mice. The pattern correlates with the abundance of protective...
Key Gene Variants Tied to Developmental Dysplasia of the Hip and Osteoarthritis
A multinational GWAS involving 350,000 European samples identified three genetic loci—COL11A2, CALN1, and TRPM7—shared between developmental dysplasia of the hip (DDH) and hip osteoarthritis (OA). Led by Dr. Ryosuke Yamaguchi and Dr. Chikashi Terao, the study also uncovered nine loci...
Human‑scale Data Aims to Close Drug Trial Gap
90% of drugs that enter clinical trials fail. A big part of why: the models they're based on weren't trained on human biology. Mouse data, non-representative cell lines, sparse perturbation coverage. The gap between in silico predictions and what actually happens...
Establishing Impurity Specifications for Antibiotics
The FDA released a draft Level 1 guidance titled “Establishing Impurity Specifications for Antibiotics.” It offers non‑binding recommendations on setting organic impurity limits for antibiotics produced by fermentation or semi‑synthesis. The guidance applies to new drug applications, abbreviated new drug applications,...
Evercore Maintains Positive Stance on MeiraGTx Holdings Plc (MGTX) Amid Sector Revisions
Evercore ISI analyst Gavin Clark‑Gartner lowered MeiraGTx Holdings plc’s price target to $18 from $20 while retaining an Outperform rating. The adjustment was part of a sector‑wide review of small‑ and mid‑cap biotech firms ahead of second‑quarter catalysts. Earlier this...
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley lowered its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13, while maintaining an Equal Weight rating, reflecting a revised valuation after the company refocused its pipeline on BT5528 and next‑generation Bicycle conjugate programs. The shift...
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley cut its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13 while maintaining an Equal‑Weight rating, citing the company’s strategic refocus on BT5528 and next‑generation Bicycle conjugate programs. The revision also reflects a roughly 30% workforce...
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Jefferies lowered its price target for Arbutus Biopharma (ABUS) from $7.00 to $5.50 while keeping a Buy rating, citing a higher probability that Moderna will win its appeal in a patent dispute. The appeal outcome affects a potential $1.3 billion contingent...
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
Mizuho Securities raised its price target on Corbus Pharmaceuticals (CRBP) to $40 from $39 and kept an Outperform rating after the company’s Q4 results. The broker noted the stock is trading close to Corbus’s cash balance, implying limited downside risk....
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
Mizuho Securities raised its price target on Corbus Pharmaceuticals (CRBP) to $40, maintaining an Outperform rating after the company’s fourth‑quarter results. The firm highlighted that CRBP is trading near its cash balance, which it says caps downside risk. Mizuho expects...
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
Northland Research initiated coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an Outperform rating and a $25 price target, spotlighting its needle‑free epinephrine spray, Neffy, as a growth catalyst. The U.S. FDA recently revised Neffy’s labeling, removing the previous age restriction and...
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
Jefferies downgraded Replimune Group (NASDAQ:REPL) from Buy to Hold and slashed its price target to $2 after the FDA issued a complete response letter on the RP1 oncolytic therapy. The FDA’s feedback diverged from earlier Type A meeting guidance, raising...
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
Evercore ISI trimmed Fortrea Holdings (FTRE) price target to $14 from $25 while keeping an Outperform rating, citing revised near‑term assumptions in its Q1 healthcare technology update. The change coincides with FTRE’s launch of Fortrea Intelligent Technology (FIT), an AI‑enabled...
Could Alzheimer’s Begin in the Nerves, Not the Brain?
University of Central Florida researchers used a human‑on‑a‑chip neuromuscular‑junction model to show that familial Alzheimer’s mutations can impair peripheral nerves and muscle connections independent of the brain. The study demonstrates that balance and gait problems in Alzheimer’s may originate in...
Stable Weight Maintenance Predicts Longer Lifespan in Mice
Longitudinal analysis of body weight reveals homeostatic and adaptive traits linked to lifespan in diversity outbred mice "We observed that the ability to maintain stable body weight, despite fluctuations in energy intake and expenditure, was positively associated with lifespan in an...
STAT+: FDA Eyes Expanding Testosterone Therapy for Libido
The FDA is reviewing data that could broaden testosterone‑replacement therapy to include low libido as an approved indication, a move that would extend the drug’s market beyond hypogonadism. If cleared, the label change could add roughly $1.5 billion in annual U.S....
Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch
Eli Lilly’s newly approved oral obesity drug Foundayo recorded 1,390 prescriptions in its first two days, a modest start compared with Novo Nordisk’s oral Wegovy, which logged over 3,000 patients in its inaugural week. RBC Capital Markets noted the timing difference—Foundayo launched...
Biovac Gets $108M Backing for Vaccine Factory in South Africa
Biovac announced that its new vaccine manufacturing complex in Cape Town has secured $108 million in financing from the European Investment Bank, the European Commission, and the International Finance Corporation. The plant is designed to produce up to 400 million doses per...
TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR
Ultima Genomics unveiled ultra‑sensitive ctDNA detection using its ppmSeq platform at AACR, presenting six abstracts including a plenary on TRACERx MRD data. A pilot of 50 plasma samples demonstrated analytical sensitivity at low single‑digit parts‑per‑million, while independent studies showed >99.9%...
Revolution Medicines' Buyout Price Soars After Pancreatic Cancer Win
Revolution Medicines announced positive Phase 3 data for its pancreatic cancer candidate, showing a statistically significant survival benefit. The breakthrough lifted the company’s market value from roughly $30 billion to an estimated $45 billion, reigniting speculation of a mega‑buyout. Investors rushed in, sending...
FDA's Proposed Peptide Rule Change Boosts Hims & Hers, Sends Mixed Signals Across Pharma
The U.S. Food and Drug Administration announced a review to lift 12 peptides from Category 2 restrictions, prompting a 9% jump in Hims & Hers stock and sparking broader industry debate over compounded peptide therapies.
STAT+: Pharmalittle: We’re Reading About Lilly Weight Loss Pill Trial Results, Slashed U.K. Clinical Trial Times, and More
Researchers led by Richard DiMarchi and Matthias Tschöp reported a novel GIP‑glucagon dual agonist that may achieve weight loss comparable to GLP‑1 drugs without the typical nausea and vomiting. In parallel, Eli Lilly announced that its new obesity pill Foundayo lowered...
MD Pharmaceutical Supply, LLC - 637815 - 11/22/2022
The FDA issued a warning letter to MD Pharmaceutical Supply, LLC after an April‑May 2022 inspection uncovered multiple CGMP violations at its Hanover, PA drug repackaging facility. The agency cited failures to investigate returned API complaints, inadequate temperature and humidity...
Future-Ready Pharma Summit
The Future‑Ready Pharma Summit gathered analytical scientists, lab managers and decision‑makers to showcase how automation, AI and digital services are reshaping small‑molecule pharmaceutical chromatography. Sessions covered AI‑driven LC method optimization, collaborative dissolution workflows, and sustainability‑focused regulatory guidance such as USP...
Taiwanese Universities Unveil Green Nanorod Sensor Platform with 0.21 µM Detection Limit
Researchers from National Central University and National Taipei University of Technology have built a green nanorod‑based electrochemical sensor that detects adrenaline at a limit of 0.21 µM. The platform uses coffee‑acid reduction to embed rhenium nanoparticles in hollow ZnMn₂O₄ microspheres, offering...
Therapy for Brain Injuries in Infants Bags Funding: Is the First HIE Drug on the Way?
ReAlta Life Sciences raised $40 million to finish its phase 2 STAR trial of pegtarazimod, a first‑in‑class drug that blocks both complement C1 and neutrophil pathways to treat hypoxic‑ischemic encephalopathy (HIE) in newborns. HIE affects about 8,000 U.S. infants annually, causing 15‑20%...
Alamar Biosciences Upsizes IPO, Raises $191.3 M to Accelerate Cell‑Based Drug Discovery
Alamar Biosciences priced an upsized initial public offering of 11.25 million shares at $17 each, generating $191.3 million in gross proceeds. The capital will fund the expansion of its cell‑based drug discovery platform, positioning the company for broader partnerships and a Nasdaq...
Obesity, GLP-1s, and Metabolic Care
In an interview, hVIVO’s Chief Medical Officer Professor Thomas Forst explains how GLP‑1 receptor agonists have reshaped obesity treatment by targeting metabolic dysfunction rather than just weight loss. He highlights that these drugs reduce cardiovascular events, improve renal outcomes and...
Metformin Misses Target in Type 1 Diabetes Trial
As a medical school professor, I love when medicine humbles us. Metformin has been around for a century. We thought we understood it. We were wrong. A new clinical trial gave metformin to people with type 1 diabetes -- not type 2....
Rejecting Life Extension = Costly, Intentional Aging Choice
"If you have access to life extension therapies and decline them, you’re making a deliberate choice to age and die on an old biological timeline." -- the additional medical cost associated with NOT choosing these therapies, may make it an...
RFK Jr. Defends Makary, Claims Pharma ‘Owns’ Congress and Media
Health Secretary Robert F. Kennedy Jr. defended FDA Commissioner Marty Makary during a Ways and Means Committee hearing, praising the agency’s recent drug‑approval record and rejecting criticism from the pharmaceutical industry. He highlighted the FDA’s decision to reject Replimune’s oncolytic...
Inside Moderna's Vision: Trust, Safety, and mRNA Future
Awesome to see @WSITYpod interview @moderna_tx president Stephen Hoge A great and wide reaching interview about trust, mRNA vaccines, spike protein, adverse events and what the future of mRNA technology is A candidate interview worth listening too.
AP-1 Activation Emerges as New Cancer Resistance Target
The knowledge of the many mechanisms by which cancer proves resistant to treatments keeps expanding. This week @Nature highlights activation of the AP-1 transcription factors, representing a new target https://t.co/UWSYDFM0IK https://t.co/6l4TISQonQ
NIH Researchers Discover Pain-Relieving Drug with Minimal Addictive Properties
NIH scientists have identified a novel nitazene‑derived opioid, DFNZ, that delivers potent, two‑hour pain relief in rats without causing respiratory depression, tolerance or significant withdrawal. The compound briefly enters the brain yet sustains analgesia, and unlike traditional opioids it fails...
Anemia May Heighten Alzheimer’s Risk Alongside P‑tau217
In evaluating p-tau217 and other biomarkers for risk of Alzheimer's disease, keep an eye on anemia, which may add to the risk, as seen in this new report https://t.co/ezbcLr4HIf https://t.co/TOKLRVBM4f
Gut Microbiome Predicts Melanoma Recurrence Post-Immunotherapy
Gut microbiome markers predict recurrence of cancer after immunotherapy for metastatic melanoma @CellCellPress https://t.co/k5YuNnqfvt https://t.co/9UbuNAcYJh
LEO Pharma’s Enstilar Receives the NMPA Approval for Plaque Psoriasis
LEO Pharma’s topical aerosol foam Enstilar, combining calcipotriene and betamethasone dipropionate, received approval from China’s National Medical Products Administration for adult plaque psoriasis. The approval follows a Phase III trial of 604 Chinese patients that demonstrated superior efficacy and safety versus...
Lilly's Obesity Pill Gains Momentum; OpenAI Launches Discovery Tool
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool https://t.co/upwygATKAv $LLY $GILD $JANX #biotech
Hands‑on PCA & CCA Tutorial for Cell Annotation
want to understand PCA projection and CCA for cell type annotation?my hands-on tutorial for cell type annotation is at https://t.co/lxePZCuypY https://t.co/hhrIQBcxll
Friday Hope: Palmitoylethanolamide (PEA): Inhibits Spike Entry, Reduces Proinflammatory Markers in COVID and Improves Symptomology in Long COVID
Recent peer‑reviewed studies demonstrate that palmitoylethanolamide (PEA), a naturally occurring lipid, can block SARS‑CoV‑2 spike protein entry, cut viral replication by roughly 70%, and lower key inflammatory biomarkers in acute COVID‑19 patients. A separate real‑world cohort shows PEA supplementation markedly...
YTE Poised as 2026's CRISPR-Like Biotech Breakout
YTE is to 2026 $XBI as CRSIPR was to 2021 $XBI $SYRE $ORKA $APGE https://t.co/CAuGPf5Hyk
Ribupatide Must Shine; Late GLP‑1 Faces Market Hurdles
All I'm going to say is that ribupatide needs to be a helluva drug for any of this to make sense. A me-too GLP-1 coming in a decade late seems like a big commercial challenge. $KLRA https://t.co/MAmA5f6FZ8
Join Dr. Robert Califf on Future of Drug Regulation
We are so excited to host Dr. Robert Califf on April 20th, 2026, at 3pm EST. From leading the U.S. Food and Drug Administration to shaping the future of clinical research and drug regulation, Dr. Califf has been at the center...